|Videos|April 14, 2023

Understanding and Mitigating the Cardiometabolic Risks of ADT

Dr Higano explains how the use of ADT in patients with prostat ecancer may impact metabolic and cardiovascular (CV) risk factors, and shares best practices on optimizing risk assessment, mitigation, and monitoring for these factors.

January 2023 AbbVie Inc. Company Confidential

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME